Renal Dosing for Benzonatate
No dose adjustment of benzonatate is required for any degree of renal impairment, including severe renal dysfunction. The FDA-approved dosing remains 100-200 mg three times daily (maximum 600 mg/day) regardless of creatinine clearance 1.
Standard Dosing Across All Renal Function Levels
Benzonatate dosing is straightforward and does not require modification based on kidney function:
- Normal renal function (CrCl ≥ 90 mL/min): 100-200 mg orally three times daily as needed
- Mild renal impairment (CrCl 60-89 mL/min): 100-200 mg orally three times daily as needed
- Moderate renal impairment (CrCl 30-59 mL/min): 100-200 mg orally three times daily as needed
- Severe renal impairment (CrCl < 30 mL/min): 100-200 mg orally three times daily as needed
- Maximum daily dose: 600 mg in all patients, regardless of renal function 1
Rationale
The FDA labeling for benzonatate contains no warnings, precautions, or dosing adjustments related to renal impairment 1. This is consistent with benzonatate's pharmacology—it is a non-narcotic antitussive that acts locally on stretch receptors in the respiratory passages and is chemically related to para-aminobenzoic acid derivatives rather than being primarily renally cleared.
Critical Safety Considerations (Unrelated to Renal Function)
While renal dosing is not a concern, several important safety issues must be emphasized:
- Capsules must be swallowed whole—never chewed, crushed, or dissolved, as release in the mouth causes local anesthesia and choking risk 1
- Pediatric deaths have occurred from accidental ingestion in children under 10 years; keep out of reach 1
- Adult overdose can be fatal within one hour, with symptoms including restlessness, tremors, convulsions, and cardiac arrest 1
- Single dose should not exceed 200 mg 1
Contrast with Other Medications
This lack of renal adjustment contrasts sharply with many other medications where dose reduction is essential. For comparison, the evidence provided shows that drugs like oseltamivir require dose reduction to 75 mg once daily (from twice daily) when CrCl is 10-30 mL/min 2, 3, and apremilast requires reduction from 30 mg twice daily to 30 mg once daily when CrCl < 30 mL/min 4. Benzonatate requires no such modifications.